Danofloxacin (CAS 112398-08-0)

EXOSC10 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of EXOSC10, a protein encoded by the EXOSC10 gene. EXOSC10, also known as the exosome component 10 or RRP6, is a crucial part of the exosome complex, which is involved in the degradation and processing of various RNA molecules within the cell. The exosome complex plays a vital role in maintaining RNA homeostasis by degrading defective or unnecessary RNA molecules, processing precursor RNAs into their mature forms, and participating in the regulation of gene expression at the post-transcriptional level. EXOSC10, in particular, has 3′-5′ exonuclease activity, which is essential for trimming and degrading RNA substrates. Structurally, EXOSC10 inhibitors can encompass a wide range of molecules, including small organic compounds, peptides, or larger biomolecules that are engineered to interact specifically with the catalytic domain or other functional regions of the EXOSC10 protein. These inhibitors typically function by blocking the active site of EXOSC10, preventing it from binding to and degrading RNA molecules. By inhibiting EXOSC10, these compounds can disrupt the normal RNA processing and degradation pathways, leading to the accumulation of RNA substrates that would otherwise be processed or degraded. The study of EXOSC10 inhibitors is crucial for understanding the mechanisms of RNA metabolism and the broader implications of RNA homeostasis on cellular function. Research into these inhibitors provides valuable insights into the regulatory networks that govern RNA stability and turnover, highlighting the importance of the exosome complex in maintaining cellular RNA levels and ensuring proper gene expression. By exploring the effects of EXOSC10 inhibition, scientists can gain a deeper understanding of the physiological and biochemical pathways influenced by RNA processing and degradation, revealing the significance of these processes in cellular homeostasis and function.